heart failure - search results
If you're not happy with the results, please do another search
ESC 2023: AF ablation improves outcomes in end-stage heart failure patients
Atrial fibrillation (AF) ablation is associated with lower rates of death, urgent heart transplantation or left ventricular assist device (LVAD) implantation compared with medical...
Forxiga granted approval from China’s NMPA for treatment of symptomatic chronic heart failure
AstraZeneca’s Forxiga (dapagliflozin) has been approved in China for use in adults with symptomatic chronic heart failure.
The drug has previously been approved in China...
First patient enrolled in global study of heart failure device trial
Heart failure start-up Acorai has announced the initiation of a global clinical trial with the enrolment of its first patient in London, UK.
The Acorai...
First US patients implanted with FIRE1 remote heart failure monitoring system
FIRE1 has announced that the first US patients have been successfully implanted with its FIRE1 system for remote heart failure monitoring in an early...
BioCardia announces FDA review completion of ongoing cell therapy for heart failure pivotal study
BioCardia, a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, has announced that the US Food and Drug...
MONITOR-HF trial results show improvement in quality of life scores for heart failure patients...
New data presented from an investigator-sponsored European trial found managing indicated heart failure patients with Abbott’s CardioMEMS HF system resulted in a significant improvement...
HRS 2023: SOLVE-CRT results “offer new hope for patients with hard-to-treat heart failure”
Results from a pivotal clinical trial found a leadless pacemaker can deliver cardiac resynchronisation therapy (CRT) among patients who were not able to be...
EHRA 2023: Novel score predicts heart failure following atrial fibrillation ablation
A score based on four readily available clinical and imaging parameters identifies the heart failure patients who benefit most from atrial fibrillation (AF) ablation, according...
Smart watches could predict higher risk of heart failure and arrhythmia
Wearable devices such as smart watches could be used to detect a higher risk of developing heart failure and irregular heart rhythms in later...
PADN-5 study results “exciting” for pulmonary artery denervation in heart failure and CpcPH patients
Results from the PADN-5 study, investigating the efficacy and safety of pulmonary artery denervation in the treatment of combined postcapillary and precapillary and pulmonary...
Aortix pMCS pump provides “rapid” decongestion for patients with heart failure and renal impairment
Procyrion, a medical device company which aims to improve outcomes for patients with cardiac and renal impairment, announced today that use of its Aortix...
Remote monitoring improves survival in heart failure patients analysis finds
Abbott has today announced new data that found monitoring patients remotely with haemodynamic pressure sensing technology, such as with its CardioMEMS HF System, can...
Analysis of NIS database shows racial disparities in atrial fibrillation outcomes in heart failure
Using data from a large and “nationally representative” sample of the US population, a recent study is the first—the authors posit—to demonstrate racial differences...
Systemic delivery of extracellular vesicles reduces AF in heart failure with preserved ejection fraction
A recent study has provided new mechanistic insights identifying distinct atrial electrophysiological remodelling and fibrosis-associated conduction abnormalities favouring atrial fibrillation (AF) susceptibility in heart...
BioVentrix receives FDA expanded access program approval for ischemic heart failure treatment system
BioVentrix, a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse...
UK regulator approves dapagliflozin for use in heart failure across the full spectrum of...
AstraZeneca has today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a licence extension for dapagliflozin (Forxiga) in Great Britain...
Ultromics EchoGo Heart Failure AI solution gains FDA clearance
Ultromics’ EchoGo Heart Failure, an artificial intelligence (AI) solution for echocardiography with the potential to revolutionise the diagnosis of heart failure with preserved ejection...
Catheter ablation shown to reduce mortality and hospitalisation in patients with atrial fibrillation and...
An analysis of randomised controlled trials (RCTs) has found catheter ablation reduces mortality and heart failure hospitalisations in patients with atrial fibrillation (AF) and...
CVRx launches new version of neuromodulation device intended to treat heart failure
CVRx—the developer of the “world’s first” US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new...
New funding for research to examine use of blood pressure cuffs for heart failure...
A research project at the University of Leeds (Leeds, UK) aiming to find an easier way to establish the optimum heart rate for heart...
AF after surgery is linked to an increased risk of heart failure hospitalisation
People who develop an arrhythmia after surgery have an increased risk of subsequently being admitted to hospital with heart failure, according to a study...
“Hybrid” model likely to be a hallmark of the post-pandemic era for heart failure...
The pandemic saw a boom in the use of remote technologies and telehealth for patient monitoring and management, including for patients with heart failure—and...
Abbott’s CardioMEMS HF system receives FDA approval for use in earlier-stage heart failure
Abbott has announced that the US Food and Drug Administration (FDA) has approved an expanded indication for the company’s CardioMEMS HF system to support...
Corvia atrial shunt fails to reduce heart failure events in REDUCE LAP-HF II trial
The placement of an interarterial shunt device—the Corvia atrial shunt (Corvia Medical)—did not reduce the total rate of heart failure events in a population...
Breakthrough designation granted to CardiaAMP cell therapy system for heart failure treatment
BioCardia has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP cell therapy system for the...
US physicians “among nation’s first” to implant neurostimulator technology for advanced heart failure
Doctors at St David's Medical Center in Austin, USA recently implanted a new neurostimulator technology in patients to help treat advanced heart failure—and are...
EMPAKT CHF trial points to change in assessment acute heart failure patients
FAST BioMedical has announced the publication of additional results from the EMPAKT CHF (Estimating versus Measuring Plasma Volume and Kidney Function in Acute Decompensated...
AI algorithm learns to predict heart failure through subtle ECG changes
An artificial intelligence (AI)-based computer algorithm created by researchers at the Mount Sinai Health System (New York, USA) has been able to learn how...
ESC 2021: GUIDE-HF shows reduction in heart failure hospitalisations using CardioMEMS
Abbott has announced results of the landmark GUIDE-HF clinical trial, a 1,000 patient randomised study designed to assess the benefits of the CardioMEMS HF...
ESC 2021: New guidelines for the diagnosis and treatment of acute heart failure published
The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic heart failure are published online today in European...
Algorithm predicts heart failure hospitalisations
Biotronik has announced the results from a new study published in EP Europace this week confirming that heart failure (HF) decompensation can be predicted...
HRS 2021: Early rhythm control benefits AF patients with heart failure
Rhythm control therapy offers a clinical benefit when initiated within one year of a diagnosis of atrial fibrillation (AF) in patients with signs or...
Remote heart failure monitoring platform offered to Imperial College patients
Imperial College Healthcare NHS Trust (London, UK) is working with remote healthcare developer, Luscii, to provide an at-home monitoring platform to support patients with...
RAFT-AF fails to show benefit of AF ablation in heart failure patients
Among patients with both heart failure and atrial fibrillation (AF), treatment strategies focused on rhythm control, using catheter ablation, and those focused on rate...
Pulmonary artery proportional pulse pressure monitoring could improve survival for heart failure patients
A new physiological measurement of heart function could improve survival for people with heart failure by identifying high-risk patients who require tailored treatments, a...
Abbott initiates trial focusing on twin AF and heart failure treatments
Abbott has announced a new trial focused on improving the treatment for people simultaneously battling both atrial fibrillation (AF) and heart failure.
The TAP-CHF trial...
Hospitalised COVID-19 patients at risk of developing heart failure
Patients hospitalised with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease...
Index-beat approach improves diagnosis of heart failure in AF patients
An assessment method known as the index-beat approach could improve the diagnosis of heart failure in patients with atrial fibrillation (AF), authors of a...
AF burden at six months predictive of hard clinical outcomes in heart failure
Atrial fibrillation (AF) burden at six months after catheter ablation is predictive of all-cause mortality and heart failure hospitalisation, in AF patients with heart...
Societies collaborate to develop universal heart failure definition
A global collaboration between international heart failure bodies seeks to standardise the language and practices around the definition and classification of heart failure around...
Analysis of REVERSE trial points to CRT benefit for heart failure patients
Medtronic has announced new results from the REVERSE trial, evaluating outcomes of cardiac resynchronisation therapy (CRT) for patients with mild heart failure (HF). The...
Urgent action needed to address growing burden of heart failure
Urgent action is needed to address the growing burden of heart failure and the impact of COVID-19 in the UK, according to a report...
Global heart failure cases soar since 1990
The number of patients with heart failure worldwide nearly doubled from 33.5 million in 1990 to 64.3 million in 2017 according to research published...
First patients enrolled in study of LINQ ICM to detect heart failure risk
Medtronic has announced the first enrolments in the ALLEVIATE-HF clinical trial which will evaluate the ability of its Reveal LINQ insertable cardiac monitor (ICM)...
Women taking beta blockers for hypertension may have higher risk of heart failure with...
Women taking beta blockers for hypertension with no prior history of cardiovascular disease have a nearly 5% higher risk for heart failure than men...
Smartphone app can identify lung congestion in heart failure patients
Voice analysis by a smartphone app can identify lung congestion in heart failure patients, allowing early intervention before their condition deteriorates, a study presented...
ESC to stream the latest science in heart failure
The European Society of Cardiology (ESC) has announced that the HFA Discoveries online event will be running six days of live sessions from 5...
COVID-19: Optimising heart failure management in the patient’s home
Physicians already recognised the importance of remote management for heart failure patients long before the COVID-19 pandemic. However, the current situation has heightened the...
Heart Failure 2020 in Barcelona cancelled
The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has announced that Heart Failure 2020 & the World Congress on Acute...
Wearable sensor analytics platform predicts worsening heart failure prior to hospitalisation
Wearing an adhesive patch sensor that streams data to an analytical platform can accurately predict worsening heart failure (HF) and the need for hospitalisation...
US FDA approves Farxiga for reduction in risk of heart failure hospitalisations in type...
The US Food and Drug Administration (FDA) has approved Farxiga (dapaglifozin, AstraZeneca) to reduce the risk of hospitalisation for heart failure in adults with...
FDA grants Fast-Track designation to develop heart failure drug
The US Food and Drug Administration (FDA) has granted Fast Track designation for the development of dapagliflozin (Farixga, AstraZeneca) to reduce the risk of...
ESC 2019: Registry study supports use of ICDs for primary prevention in patients with...
New data from the Swedish Heart Failure Registry indicate the use of an implantable cardioverter defibrillator (ICD) in patients with heart failure with reduced...
ICD implantation can be used for primary prevention in asymptomatic heart failure
Asymptomatic heart failure patients are likely to benefit from prophylactic implantable cardioverter defibrillator (ICD) treatment, irrespective of cardiomyopathy aetiology, according to the findings from...
New Australian research and development partnership aims to innovate heart failure care
Biotronik, the University of Newcastle (Callaghan, Australia) and the Hunter New England Local Health District (HNE LHD) have partnered to shape a heart failure care model. To...
Positive 12-month data presented for CardiAMP Cell Therapy System for heart failure
Positive 12-month data have been presented for the roll-in cohort of the pivotal CardiAMP Heart Failure Trial studying the investigational CardiAMP Cell Therapy System...
US FDA approve HeartMate 3 heart pump advanced heart failure patients not eligible for...
The HeartMate 3 left ventricular assist device has received US FDA approval as a destination therapy for people living with advanced heart failure. With...
LivaNova launches international pivotal study evaluating use of autonomic regulation therapy for heart failure
LivaNova has announced the first successful implantation of the Vitaria system in a patient enrolled in the Autonomic regulation therapy to enhance myocardial function...
ESC: European Society of Cardiology Heart Failure 2019
W: www.escardio.org
VisONE system for heart failure implanted for first time
VisCardia has announced the first implant of its VisONE implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study...
Clinical trial to evaluate ECG belt for optimising heart failure therapy launches
Medtronic has announced the first enrolments in a new clinical trial evaluating the ECG (electrocardiography) Belt Research System (ECG Belt) as a diagnostic tool...
Boston Scientific launches the HeartLogic heart failure diagnostic in Europe
Boston Scientific Europe has announced the launch of the HeartLogic Heart Failure Diagnostic in Europe. With this launch, the first and only diagnostic tool...
Heart Failure 2018
W: www.escardio.org
Cardiac contractility modulation in heart failure treatment is safe
Cardiac contractility modulation (CCM) in heart failure is safe, the results from the FIX-HF-5C randomised controlled trial demonstrate, with all primary and secondary safety...
Successful ablation for ventricular tachycardia associated with markedly reduced mortality in advanced heart failure...
Wendy Tzou (University of Colorado School of Medicine, Denver, USA) and colleagues at the International Ventricular Tachycardia Ablation Center Collaborative group (IVTCC) published two...
IMPLANTED suggests link between physical activity and atrial arrhythmias in heart failure patients
Low level of daily physical activity was associated with a higher risk of atrial arrhythmias in heart failure patients with implantable devices. A low...
Catheter ablation lowers mortality in atrial fibrillation patients with heart failure
Catheter ablation of atrial fibrillation significantly reduces mortality and hospitalisation in atrial fibrillation patients with heart failure in comparison with conventional treatment, data from...
Data confirm HeartLogic Diagnostic helps to categorise patients at low or high risk of...
Boston Scientific has announced new data from the MultiSENSE (Multisensor chronic evaluation in ambulatory heart failure patients) study, which is evaluating the performance of...
Heart failure patient and clinician risk perceptions differ drastically
Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death while...
Gaining a few pounds may increase long-term heart failure risk
Gaining even a little weight over time may alter the structure and function of heart muscle, affecting long-term risk of heart failure, according to...
Late-breaking trials identify early onset of heart failure and lack of defibrillators in Asia...
For the first time this year, late-breaking clinical trials session were held at the Asian Pacific Society of Cardiology (APSC) Congress, to highlight world-class...
The Sound Doctor releases 40 heart failure films for patients
The Sound Doctor, a UK-based provider of health-related film and audio content for patients, has announced a series of 40 films on heart failure.
The...
23rd European Heart Disease and Heart Failure Congress
W: www.heartdiseases.conferenceseries.com
Timing of menopause onset associated with increased heart failure risk in women
Postmenopausal women who reached menopause at an earlier age or who never gave birth are at a higher risk for heart failure, according to...
Heart failure patients readmitted to the same hospital may have better outcomes
When patients with heart failure were re-hospitalised within a month, those who returned to the same hospital were discharged quicker and were more likely...
Unemployment associated with 50% higher risk of death in heart failure patients
Unemployment is associated with a 50% higher risk of death in patients with heart failure, according to research presented at Heart Failure 2017 and...
Heart failure mortality is inversely related to wealth of country
Death in patients with heart failure is inversely related to the wealth of the country they live in, according to late breaking results from...
ACC 2017: Real-world study supports the effectiveness of the CardioMEMS HF system in reducing...
A study outside the clinical trial setting, which included US Medicare patients, has shown the effectiveness of the CardioMEMS HF system (Abbott) to significantly...
Biomarkers accurately predict acute kidney injury risk in acute decompensated heart failure patients
Newly published findings suggest that certain urinary biomarkers could help clinicians identify risk of acute kidney injury in patients with acute decompensated heart failure....
ACC 2017: More hospitalisations and deaths for US heart failure patients in winter
Patients with heart failure in the USA are more likely to be hospitalised and more likely to die during the colder winter months, according...
Increased physical activity, lower BMI may lower heart failure risk
While lifestyle patterns, including physical activity and body mass index (BMI), are associated with overall heart failure risk, they are more strongly associated with...
Flu, pneumonia vaccines may improve health of heart failure patients
Flu and pneumonia vaccines may improve the quality of life and outcomes of heart failure patients by providing cost-effective protection against life-threatening respiratory infections,...
Latest statistics show heart failure on the rise
The number of adults living with heart failure increased from about 5.7 million (2009-2012) to about 6.5 million (2011-2014), according to the American Heart...
Educational Supplement ‒ St. Jude Medical: Tackling heart failure with innovative options
This educational supplement is only available in countries outside the USA.
This educational supplement contains highlights of the 5th edition of The Future of Heart...
4th World Congress on Acute Heart Failure
W: www.escardio.org/HFA
Transcatheter atrial shunt benefits persist through one year in treatment of heart failure patients...
Twelve-month results of the REDUCE LAP HF (Reduce elevated left atrial pressure in patients with heart failure) trial have shown both continued device patency...
Insights into current heart failure management
Piotr Ponikowski (Centre for Heart Disease, Clinical Military Hospital, Wroclaw, Poland), chairperson of the 2016 European Society of Cardiology (ESC) Guidelines for the diagnosis...
AHA 2016: Multisensor algorithm may help predict worsening heart failure
Results from the MultiSENSE study have demonstrated that a new multisensor algorithm, the HeartLogic Heart Failure Diagnostic Service (Boston Scientific), provides a timely alert...
AHA 2016: Elizabeth M McNally wins AHA prize for research into genetic flaws responsible...
The American Heart Association (AHA) awarded its Basic Research Prize for 2016 to Elizabeth M McNally (Chicago, USA) for “Ground-breaking investigations of novel genetic...
AHA 2016: Combination of drug therapy and left ventricular assist device helps severe heart...
More than a third of advanced heart failure patients treated with a left ventricular assist device (LVAD) and intensive drug therapy have recovered their heart function enough...
Biotronik launches Inventra ICD for heart failure patients with higher defibrillation thresholds
Biotronik has announced the US launch of Inventra HF-T, an implantable cardioverter defibrillator (ICD) that delivers “ultra-high” energy with 42 joules (J) on the...
Medtronic gets FDA approval for MRI compatible cardiac rhythm and heart failure devices
Medtronic has announced US Food and Drug Administration (FDA) approval for its suite of cardiac rhythm and heart failure devices and leads to be...
Painkillers linked to increased risk of heart failure
Commonly used prescribed painkillers for treating pain and inflammation are associated with an increased risk of hospital admission for heart failure, finds a study...
ESC 2016: Remote monitoring for heart failure may not improve clinical outcomes
Two randomised clinical trials presented at a Hot Line session of the European Society of Cardiology Congress (ESC; 27‒31 August, Rome, Italy) have shown...
ESC 2016: Rethink of ICD implantation in non-ischaemic heart failure may be on the...
Implantable cardioverter-defibrillators (ICDs) do not improve overall long-term survival compared to medical treatment in patients with non-ischaemic systolic heart failure, according to results of...
New alliance for heart failure calls for improved care for condition
A coalition of charities, patient groups, professional bodies and healthcare companies with an interest in heart failure has been established to raise the profile...
Atrial fibrillation and heart failure: The ugly and the nasty
W: www.bk1.it/events
MultiPoint™ pacing CRT technology shows promise in improving heart failure responder rates
A growing body of evidence, including the most recent randomised clinical trial results presented at HRS and CARDIOSTIM-EHRA EUROPACE, has shown that cardiac resynchronisation therapy...
Cardiac resynchronisation therapy with SonR automated feature helps to reduce hospitalisation rates in heart...
Results from the RESPOND-CRT trial have shown a 35% risk reduction in hospitalisation at two years for heart failure patients implanted with cardiac resynchronisation...
Insights into genetically-targeted prevention of atrial fibrillation in heart failure patients
The current need for new preventative therapies of atrial fibrillation in chronic heart failure patients—with fewer side effects than currently available treatment strategies—has led...
Many drugs can cause or worsen heart failure, American Heart Association cautions
Commonly used medications and nutritional supplements may cause or worsen heart failure, according to the first scientific statement from the American Heart Association to...
Wireless CRT has the potential to improve response in heart failure patients
The world’s only wireless endocardial pacing system for cardiac resynchronisation therapy (CRT)—WiSE (Wireless Stimulation of the Endocardium) CRT System (EBR Systems)—is showing promise treating...
St Jude CardioMEMS HF system becomes ESC’s guideline-directed therapy for heart failure
St Jude Medical’s CardioMEMS heart failure (HF) system has been added to the European Society of Cardiology (ESC) guidelines as a directed therapy management...
Catheter ablation is superior to amiodarone in the treatment of patients with heart failure...
New research indicates that catheter ablation may achieve greater long-term freedom from atrial fibrillation, as well as a reduction in unplanned hospitalisation and mortality...
Heart Failure Congress
W: www.escardio.org
Rethink of ICD implantation in non-ischaemic heart failure may be on the cards
Implantable cardioverter-defibrillators (ICDs) do not improve overall long-term survival compared to medical treatment in patients with non-ischaemic systolic heart failure, according to results of...
Empagliflozin (Jardiance) to be studied for the treatment of people with chronic heart failure
Boehringer Ingelheim and Eli Lilly are to conduct two outcome trials investigating the diabetes medicine empagliflozin (Jardiance) for the treatment of people with chronic heart failure.
INOVATE-HF data show no evidence that vagus nerve stimulation reduces death in heart failure
Results from the INOVATE-HF trial indicate that vagus nerve stimulation does not reduce the rate of death or heart failure events in chronic heart failure patients. The data were simultaneously presented at ACC 2016 and published in the Journal of the American College of Cardiology.
American Heart Association warns that African Americans and Hispanics face greater heart failure risk
Studies have shown that heart failure affects African American individuals with roughly twice the incidence of that of Caucasians. The Hispanic population has the second-highest risk of developing heart failure in the USA.
Women and men with heart failure benefit similarly from implantable cardioverter defibrillators
An analysis from the US Get with the guidelines for heart failure registry has found that women and men with heart failure and reduced left ventricular ejection fraction benefit similarly from implantable cardioverter defibrillators.
Using the American Heart Association’s seven measures for heart health may reduce heart failure...
Scoring highly on the American Heart Association (AHA)'s Life's Simple 7 checklist has been associated with a reduction in heart failure risk, according to a study published Circulation: Heart Failure.
Leading heart failure doctors pledge united action to improve patient outcomes
Leading heart failure doctors from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) have united in a pledge to improve patient outcomes and reduce the burden of heart failure on society.
Novartis’ Entresto receives European authorisation for chronic heart failure treatment
Novartis' Entresto (sacubitril/valsartan) has been authorised for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
CardioKinetix announces South Korean approval for the Parachute System for heart failure
Regulatory approval has been granted in South Korea for the Parachute System by CardioKinetix by the Korean Ministry of Food and Drug Safety (MFDS).
First wireless cardiac pacing system for heart failure receives the CE mark
EBR Systems has announced the CE mark approval for its Wise (Wireless stimulation endocardially) technology, which is the world's only wireless endocardial pacing system for cardiac resynchronisation therapy (CRT).
Benefits of autonomic regulation therapy for heart failure are maintained after 12 months, ENCORE...
Data show that autonomic regulation therapy in patients with moderate to severe chronic heart failure and impaired heart function is well tolerated, safe, improves the heart's ability to pump blood, and reduces the frequency and severity of symptoms associated with chronic heart failure.
Simple test predicts obstructive sleep apnoea in patients hospitalised for heart failure
Researchers at Thomas Jefferson University, Philadelphia, USA, have showed that a simple questionnaire, evaluation and pulse-oximetry monitoring can lead to early detection of sleep apnoea in patients hospitalised for congestive heart failure.
BioControl Medical completes enrolment in the INOVATE-HF study of the CardioFit system to treat...
INOVATE-HF has enrolled a total of 725 patients at 86 centres in the USA and Europe, making it the largest prospective, randomised device study to evaluate the treatment of heart failure with vagus nerve stimulation.
Moderate physical activity associated with lower risk of heart failure in men
A new study shows that walking and cycling for 20 minutes per day has greatest impact on lowering the risk of heart failure.
Continuous monitoring of heart failure patients feasible with implantable cardiac microchip
CardioMEMS (St Jude Medical), FDA approved in 2014, is a minimally invasive device used to measure the pulmonary artery pressures and heart rates of...
LCZ696 (Entresto) gets FDA approval for heart failure treatment
Novartis has announced that the US Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, for the treatment of heart failure with reduced ejection fraction.
American Heart Association survery indicates potentially dangerous misconceptions about heart failure
The data from the American Heart Association will inform ongoing efforts and outreach about heart failure in the USA.
Baroreflex activation therapy shows greater benefits in no-CRT heart failure patients
A phase II study onbaroreflex activation therapy treatment for heart failure patients with a reduced ejection fraction has found greater benefits for patients without a cardiac resynchronisation therapy device than for patients with one.
Catheter ablation superior to amiodarone for patients with persistent atrial fibrillation and heart failure
Speaking at the 2015 American College of Cardiology Annual Scientific Session, Luigi Di Biase reported that-compared with the antiarrhythmic drug amiodarone-catheter ablation significantly increases the rate of freedom of recurrence in patients with persistent atrial fibrillation and heart failure.
ResMed to present data on sleep-disordered breathing in chronic heart failure patients at ACC...
Data from the two studies will be presented at the 64th Annual Scientific Sessions of the American College of Cardiology (ACC) (14-16 March, San Diego, USA).
A new study explores heart failure treatment with vagal nerve stimulation
Albert Hagège (Georges Pompidou European Hospital in Paris, France), principal investigator of Vanguard, a new study exploring the safety and efficacy of vagal nerve...
Spinal cord stimulation in severe heart failure patients is safe and can potentially improve...
Results of a prospective, multicentre pilot trial of severe heart failure patients treated with continuous spinal cord stimulation have shown the treatment is safe and feasible with the Eon Mini neurostimulation device (St Jude Medical) and can potentially improve symptoms, functional capacity and cardiac function.
Vitaria vagal nerve stimulation system receives CE mark for treatment of chronic heart failure
Vitaria delivers autonomic regulation therapy for patients who have moderate to severe heart failure with left ventricular dysfunction (ejection fraction < 40%), and who remain symptomatic despite stable, optimal heart failure drug therapy.
Heart failure patients who struggle with daily tasks are hospitalised more often and die...
The risk is higher for older women, unmarried people and those with chronic conditions that affect mobility and ability, including obesity, dementia, anaemia and diabetes, researchers said.
Stem cells from placenta show promise for treating heart failure
A new study has examined the therapeutic effects of PDA-001, an intravenous formulation of PDAC cells, in mice, as well as the best way to deliver the therapy.
Algisyl-LVR shows significant health status improvement of advanced heart failure patients
LoneStar Heart has presented the primary six month results of its multicentre, randomised clinical trial of Algisyl-LVR, providing evidence that the cardiac hydrogel implant can prevent or reverse the symptoms of moderate to severe heart failure in patients with a dilated and weakened left ventricle.
Studies show Medtronic CRT devices reduce readmissions after heart failure hospitalisations
New data from Medtronic show that its cardiac resynchronisation therapy devices for the treatment of heart failure can cause a significant reduction in all-cause 30-day readmissions after heart failure hospitalisations.
New positive data from investigational drug (LCZ696) for heart failure presented at AHA
New data from PARADIGM-HF have shown that the investigational angiotensin receptor-neprilysin inhibitor (ARNI) LCZ696 (Novartis) has the potential to prevent the clinical progression of surviving patients with heart failure more effectively than enalapril.
CVRx announces first successful Barostim neo heart failure commercial implants in Europe
CVRx has announced the first 10 heart failure patients treated with the Barostim neo system under CE mark approval.
Vagal nerve stimulation for heart failure requires specific lead design
Randy Lieberman (Detroit, USA) explains how lead design for vagal nerve stimulation in heart failure treatment may affect the outcome of the procedures.
Vagal...
First randomised sham controlled trial of vagal nerve stimulation for heart failure treatment fails
NECTAR-HF, the first randomised, sham-controlled trial of vagal nerve stimulation for the management of heart failure has failed to show significant difference in cardiac remodelling between vagal nerve stimulation and a sham procedure-meaning that the study has not met its pre-specified six-month primary efficacy endpoint.
New data analysis from CHAMPION shows significant reductions in heart failure hospitalisations with CardioMEMS
St Jude Medical has announced a new data analysis from the CHAMPION clinical trial-in a subgroup of patients with renal failure-that showed reduced heart failure hospitalisation by 42% for patients managed with pulmonary artery pressure based technology compared to a control group.
New drug LCZ696 superior to enalapril in heart failure treatment
Findings from the PARADIGM-HF trial have found that the investigational medicine LCZ696 (Novartis) cuts cardiovascular deaths by 20% compared to ACE inhibitor enalapril in heart failure patients with reduced ejection fraction.
Transseptal endocardial CRT: An evolving approach for heart failure patients
Néstor López Cabanillas and Elencwajg Benjamin from Buenos Aires, Argentina, write about two similar novel techniques for cardiac resynchronisation therapy (CRT) implantation, currently used...
PARADIGM-HF trial results of LCZ696 for heart failure to be presented at ESC
New data revealing the reduction in cardiovascular deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction will be presented at the European Society of Cardiology (ESC) Congress 2014.
Cardioxyl Pharmaceuticals completes first clinical trial for heart failure drug CXL-1427
Cardioxyl Pharmaceuticals has announced the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers.
Physicians implant world’s first ProMRI Quadripolar CRT-D system to treat heart failure
With Sentus quadripolar leads and the Inventra series, Biotronik offers the only devices for patients with heart failure worldwide that are approved for MRI use.
Boston Scientific welcomes new guidance on the use of cardiac technologies for patients with...
In the updated Technology Appraisal, people with ventricular arrhythmias are eligible for an ICD, which can help prevent cardiac arrest in those who have previously survived a life-threatening arrhythmia. In people with heart failure, CRT can improve life expectancy and quality of life.
Processed red meat linked to higher risk of heart failure, death in men
Men who eat moderate amounts of processed red meat may have an increased risk of incidence and death from heart failure, according to a study in Circulation: Heart Failure, an American Heart Association journal.
Preventive placement of ICDs in patients with less severe heart failure associated with improved...
An examination of the benefit of preventive placement of implantable cardioverter-defibrillators (ICDs) in patients with a less severe level of heart failure finds significantly better survival at three years than that of similar patients with no ICD, according to a study in the June 4 issue of JAMA.
FDA approves CardioMEMS heart failure system
The US Food and Drug Administration has approved the CardioMEMS heart failure system that measures the pulmonary artery pressures and heart rates of patients with New York Heart Association (NYHA) Class III heart failure who have been hospitalised for heart failure in the previous year. The device allows health care professionals to monitor the condition of their patients remotely.
Boston Scientific announces FDA approval of new defibrillators and heart failure devices
Boston Scientific has received FDA approval for its latest generation of defibrillators and heart failure devices. The newly approved devices include the Dynagen Mini and Inogen Mini ICDs, as well as the Dynagen X4 and Inogen X4 CRT-Ds.
FDA approves expanded indication for certain pacemakers and defibrillators used to treat heart failure
The US Food and Drug Administration (FDA) approved an application from Medtronic for revised labelling for two cardiac resynchronisation pacemakers (CRT-P) and eight cardiac resynchronisation defibrillators (CRT-D), expanding the indication for use to patients with atrioventricular (AV) block and less severe heart failure.
Poor sleep doubles hospitalisations in heart failure patients
Poor sleep doubles hospitalisations in heart failure, according to new research in nearly 500 patients presented at EuroHeartCare (4-5 April, Stavanger, Norway).
Long-term data show lower mortality rates in heart failure patients with Boston Scientific CRT...
In the longest follow-up to date of cardiac resynchronisation therapy (CRT) for mild heart failure patients, Boston Scientific's multicentre automatic defibrillator implantation trial - cardiac resynchronisation therapy (MADIT-CRT) study demonstrated significant and sustained survival benefit for the indicated population.
ICD-CRT therapy reduces hospitalisations compared with ICD therapy alone in heart failure patients
A subanalysis within the RAFT trial has shown significantly reduced hospitalisations with implantable cardioverter defibrillators with cardiac resynchronisation therapy (ICD-CRT) devices compared with ICD alone devices in heart failure patients.
Cardiac resynchronisation therapy with leadless technology is feasible in heart failure patients
Heart failure patients treated in the WISE-CRT study with a leadless ultrasound-based device demonstrated a significant improvement of functional status and a significant increase of left ventricular ejection fraction at six-month follow-up.
NICE consults on draft updated recommendations on implantable devices for the treatment of life-threatening...
The draft guidance from the UK's National Institute for Health and Care Excellence (NICE) defines which implantable cardiac devices are clinically and cost effective options for people with life-threatening arrhythmias or heart failure.
CHART-1 trial for cellular therapy of heart failure to enrol patients in Italy
The CHART-1 trial, according to a company release, represents the world's first phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart failure.
Heart failure patients experience 46% reduction in atrial fibrillation risk with AdaptivCRT feature in...
On 23 September, Medtronic announced clinical trial results showing that heart failure patients treated with its AdaptivCRT feature experienced a 46% reduction in atrial fibrillation risk.
BioVentrix expands use of its Revivent System for heart failure treatment with first clinical...
BioVentrix has announced the first use of its Revivent Myocardial Anchoring via less invasive ventricular enhancement (the LIVE) procedure in Germany. The successful procedure was performed on a 54-year old man suffering from advanced heart failure at the Schön Klinik Vogtareuth in Vogtareuth, Germany.
New findings for acute heart failure treatment with Trevena’s biased ligands
Trevena has announced the publication of new findings related to the mechanism of action of its Angiotensin II Type 1 Receptor (AT1R) biased ligands. The publication describes work led by R John Solaro, head of the Department of Physiology and Biophysics at the University of Illinois, Chicago, USA, performed in collaboration with Trevena scientists.
Dabigatran shows sustained benefit in difficult to treat patients with atrial fibrillation and symptomatic...
Results from a new sub-analysis of the RE-LY trial support consistent benefit of dabigatran (Pradaxa, Boehringer Ingelheim) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation and previous symptomatic heart failure.
American College of Cardiology and American Heart association update guidelines for management of heart...
The updated guideline emphasises on patient-centric outcomes such as quality of life, shared decision making, care coordination, transitions, and palliative care.
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented at the Heart Failure Congress 2013 in Lisbon, Portugal (25-28 May).
RELAX-AHF and VIVIDD trial results presented at Heart Failure Congress
Serelaxin may be more effective for relieving dyspnoea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented at a late-breaking trial session at the Heart Failure Congress (Lisbon, Portugal, 25-28 May).
Biocontrol Medical launches new website for patient and clinician education on CardioFit therapy for...
BioControl Medical has introduced a new corporate website that offers patients, family and clinicians an educational resource on its CardioFit therapy for heart failure, as well as the INOVATE-HF clinical study of the device.
CVRx launches HOPE4HF clinical trial evaluating Barostim neo in heart failure patients
The Barostim neo device is an alternative treatment to drug therapy designed to trigger the body's own natural blood flow regulation system to treat heart failure.
Electrocardiographic abnormality associated with increased risk of atrial fibrillation, congestive heart failure
Left anterior fascicular block may be a clinically relevant marker of an individual's propensity to develop atrial fibrillation or congestive heart failure, a new study has found.
Inliven CRT-P device gets CE mark to treat heart failure
Inliven (Boston Scientific) is the first cardiac resynchronisation therapy pacemaker (CRT-P) using patient's respiration signals to provide physiological pacing and comorbidity management.
The American College of Cardiology and Elsevier launch a journal dedicated to heart failure
JACC: Heart Failure is a new journal dedicated to meet the demands and challenges of treating what is now the most rapidly increasing category of cardiac disease. The first publication is now available.
Insomnia is linked to increased risk of heart failure
People who suffer from insomnia appear to have an increased risk of developing heart failure, according to a study published online in the European Heart Journal.
European Journal of Heart Failure recognises research on vagus nerve stimulation for treating heart...
BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognised as seminal original research in the European Journal of Heart Failure.
Undiagnosed sleep-disordered breathing is common but does not predict mortality in chronic heart failure...
Wolfram Grimm, Baldingerstraβe, Germany, and others reported in EP Europace that while undiagnosed sleep-disordered breathing is common in patients with implantable cardioverter defibrillators (ICD) and chronic heart failure, it does not independently predict appropriate ICD therapy or mortality.
Is “parasympathetic withdrawal” a critical factor in heart failure progression?
Randy Lieberman, director of electrophysiology at Harper University Hospital: CardioVascular Institute, Detroit Medical Center, Detroit, USA, reviews the role of the parasympathetic nervous system in heart failure.
First heart failure patient treated in the UK with novel nerve-stimulation device
This first procedure is part of the INOVATE-HF study, a clinical trial designed to study the safety and efficacy of the CardioFit system to reduce hospitalisation and death among patients with heart failure.
RAFT trial shows CRT-D therapy is cost-effective for mildly symptomatic heart failure patients
An economic analysis of the RAFT trial showed a US$33,025 cost per Quality Adjusted Life Year (QALY) gained using Medtronic CRT-Ds in a mild, New York Heart Association (NYHA)-designated Class II-III heart failure patient population.
Medtronic receives FDA approval to treat mildly symptomatic heart failure patients through expanded indication...
The FDA's decision was supported with data from the pivotal REVERSE and landmark RAFT clinical trials, which showed that CRT-D can benefit mildly symptomatic heart failure patients by reducing mortality and heart failure hospitalisation rates.
Cardiac resyncronisation therapy reduces rates of death and re-hospitalisation in heart failure patients, new...
The survey a joint initiative of the Heart Failure Association and European Heart Rhythm Association of the European Society of Cardiology (ESC) gathered information on more than 2000 patients at 141 centres in 13 European countries.
FDA Advisory Panel recommends against approval of Champion heart failure management system
While the panel agreed that the CardioMEMS technology is safe with a vote of 9-1, the majority did not vote positively that the system is effective and that reasonable assurance of the risks associated with the device outweigh the potential clinical benefits of the technology.
New RE-LY sub-analyses demonstrate safety and efficacy of Pradaxa in patients with heart failure...
Pradaxa (dabigatran etexilate) 150mg bid reduced the risk of stroke in atrial fibrillation patients with symptomatic heart failure and non-valvular atrial fibrillation compared to well-controlled warfarin.
Resynchronisation therapy shows heart failure benefit in AF patients
In patients affected by permanent atrial fibrillation (AF), cardiac resynchronisation therapy (CRT) proved superior to conventional right ventricle apical pacing in reducing the clinical manifestations of heart failure, a new study presented at Heart Rhythm 2011 has shown.
Boston Scientific begins international launch and first implants of next-generation devices to treat heart...
Energen and Punctua cardiac resynchronisation therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) are the world's smallest and thinnest high-energy devices to treat heart failure and sudden cardiac death and offer excellent longevity.
IMPROVE HF study shows adherence to outpatient quality measures associated with improved survival in...
Compliance with the implantable cardioverter defibrillator process measure in eligible patients was associated with 38% lower odds of mortality over two years, and cardiac resynchronisation therapy process measure compliance was associated with 36% lower odds of mortality.
European economic analysis shows cost benefit of CRT in mild heart failure patients
"CRT not only helps keep less sick heart failure patients out of the hospital more, but it is also a more cost-effective treatment approach than many other therapeutic options currently available," said Cecilia Linde, Stockholm, Sweden.
Boston Scientific announces CE mark approval and first implants for new devices to treat...
Incepta, Energen and Punctua CRT-Ds and ICDs designed to advance patient care with options to expand appropriate therapy, optimise ventricular pacing and manage heart failure.
FDA approves devices for heart failure patients
A new indication for three cardiac resynchronisation therapy defibrillators can be used for patients with an abnormality known as left bundle branch block.
FDA approves new CRT-D indication for heart failure patients
The three devices from Boston Scientific are intended to treat patients with left bundle branch block who have either mild heart failure or heart failure with no apparent symptoms.
Medtronic introduces new CareLink remote monitoring network for heart failure clinicians
System supports proactive patient care for patients at risk for worsening heart failure.
Telemonitoring benefits heart failure patients’ everyday lives
Ryszard Piotrowicz, head of Department of Cardiac Rehabilitaion and Noninvasive Electrocardiology, National Institute of Cardiology, Warsaw, explains the advances in the provision of cardiac rehabilitation to heart failure patients.
St Jude Medical announces European approval of smaller, higher power ICD and CRT-D devices...
The Fortify and Unify devices get CE Mark; expected to be universally available by the end of the year.
FDA Advisory Panel recommends expanded CRT indication for heart failure
The panel unanimous decision extends resynchronisation therapy for asymptomatic and mild heart failure patients based on landmark MADIT-CRT trial.
Boston Scientific’s most advanced devices to treat heart failure and sudden cardiac death now...
Cognis cardiac resynchronisation therapy defibrillator and Teligen implantable cardioverter defibrillator are the world's smallest and thinnest high-energy devices.
Study shows fluid monitoring more accurate than weight measures for heart failure patients
Results showed that Medtronic OptiVol Fluid Status Monitoring predicted 76% of future heart failure events as compared to only 23% detected by weight monitoring alone.
AF linked to increased hospitalisation in heart failure patients
Patients with atrial fibrillation, common in those with advanced chronic heart failure, have an increased risk of hospitalisation due to heart failure.
Mild heart failure: The REVERSE results
Dirk J van Veldhuisen analyses the findings on the use of CRT for heart failure patients classes I and II and how the results will impact in future studies.
Heart-failure helpline could be “difference maker” for turning disease into a manageable condition
The Stronger Hearts Helpline pilot programme centralises resources to educate and improve access to care.
Researchers map potential genetic regulators of the heartbeat
University of Texas (UT) Southwestern Medical Center researchers have mapped gene control elements in specialised cardiac cells responsible for heartbeat regulation. The findings of...
Patients with both atrial fibrillation and diabetes less likely to notice an irregular heartbeat
Adults with type 1 or type 2 diabetes and atrial fibrillation (AF) are less likely to notice irregular heartbeat symptoms, more likely to have...
Caption Health and Ultromics partner to increase availability of heart disease detection and management...
Caption Health and Ultromics have announced a strategic partnership to accelerate cardiovascular disease detection and treatment for more patients in more accessible care settings....
Continuous heart rhythm monitoring “does not prevent strokes in those at risk”
Continuous heart rhythm monitoring—with anticoagulation if atrial fibrillation (AF) is detected—does not prevent strokes in those at risk. That is the finding of the...
Ancora Heart secures US$80 million in financing
Ancora Heart has closed US$80 million in equity financing, with the funds to be used to accelerate the CORCINCH-HF pivotal clinical study of the...
B-Secur receives FDA clearance for its HeartKey EKG/ECG technology
B-Secur has announced that it has received US Food and Drug Administration (FDA) 510(K) clearance for its HeartKey software library.
B-Secur’s HeartKey is a suite...
Abbott’s HeartMate 3 LVAD receives approval for paediatric use
Abbott has announced that the US Food and Drug Administration (FDA) has approved updated labelling for the company's HeartMate 3 heart pump to be...
CardioFocus announces 10,000-patient milestone for HeartLight ablation system
CardioFocus has announced that more than 10,000 patients worldwide have been treated with the HeartLight endoscopic ablation system.
The HeartLight system is a catheter ablation...
€3.7m funding round completed for cardiac AI developer inHEART
inHEART, developer of a cloud-based medical image analysis solution for cardiac interventions on patients with arrhythmias, has closed a funding round of €3.7m led...
British Heart Foundation calls for urgent resumption of routine services for heart and circulatory...
The British Heart Foundation (BHF) is calling on the Government and the NHS to urgently address the immediate needs of heart and circulatory patients...
Cardiac Insight launches Heart@Home ECG test kit
Cardiac Insight has announced the launch of the Heart@Home electrocardiogram (ECG) test kit to address new telehealth demands placed on cardiology practices by the...
Eko receives FDA clearance for AF and heart murmur algorithms
Eko has announced that the US Food and Drug Administration (FDA) has cleared a suite of algorithms that, when combined with Eko’s digital stethoscopes,...
FDA approves Abbott heart pump for less invasive surgical approach
Abbott has announced US Food and Drug Administration (FDA) approval of a new alternative surgical technique for Abbott's HeartMate 3 heart pump that the...
Tackling focal VT may improve catheter ablation in structural heart disease
Uncovering and abolishing focal ventricular tachycardia (VT) may further improve outcomes of catheter ablation in the treatment of structural heart disease, a study published...
Apple Heart study finds low rates of AF notification, and high level of agreement...
Final results from the Apple Heart study demonstrate a low probability of receiving an irregular pulse notification. It also found that 34% of those...
First active-fixation left heart lead approved by FDA
The US Food and Drug Administration (FDA) has granted approval to Medtronic for the Attain Stability Quad MRI SureScan left heart lead. It is...
First trial of in-heart micro device for left atrial pressure monitoring launched
Vectorious Medical Technologies has announced the initiation of the VECTOR-HF first-in-human (FIH) clinical trial, and the successful first “in-human” implantation of the V-LAPTM monitoring...
First AI-driven wearable heart monitor that prevents heart disease and stroke to be released
Cambridge Heartwear is announcing the launch of their company and release of their Heartsense monitor in 2019. In the US, strokes are among the...
BioCardia submits 510(k) application to US FDA for its Avance steerable introducer for transseptal...
BioCardia has announced its 510(k) submission for US FDA clearance of the Avance steerable introducer, which is designed for introducing various cardiovascular catheters into...
HeartWare HVAD system receives US FDA approval
Medtronic has received United States Food and Drug Administration (FDA) approval for a less-invasive implant approach of its HVAD System, a left ventricular assist...
Wearable defibrillators may be an alternative to surgically implanted device for children with certain...
Wearable cardioverter defibrillators – vest-like devices that deliver electric shocks to interrupt a dangerous heart rhythm – may be a safe and effective alternative...
FDA classifies HeartWare HVAD systems unexpected power source switching as Class I recall
The United States Food and Drug Administration (FDA) has classified Medtronic recent voluntary urgent field action related to the HeartWare HVAD System unexpected power...
HeartMate 3 left ventricular assist system: Class I recall
The US FDA has issued a class I recall due to a malfunction in the device’s outflow graft assembly that may cause the outflow...
Late-breaking presentation at Heart Rhythm 2018 shows potential for more patients to benefit from...
An investigational algorithm, utilising the accelerometer signal in the Micra Transcatheter Pacing System (TPS) (Medtronic) may restore AV synchrony, improving cardiac function in patients...
HeartSciences announces publication of clinical study results
A medical device company has announced the results of a clinical study serially conducted at The Icahn School of Medicine, Mount Sinai Hospital, New...
New long-term data show improved survival and lower rates of stroke and pump thrombosis...
New late-breaking clinical trial data from the MOMENTUM 3 clinical study shows overall survival of 83% at 2-years and marked improvement in clinical outcomes for...
Class I recall: HeartStart MRx defibrillator by Philips Electronics
Philips is recalling the HeartStart MRx defibrillator due to a defect in the device's gas discharge tube. The gas discharge tube has micro cracks...
Congenital heart disease in children and young adults have 22 times higher risk of...
A study published in the Circulation journal has shown that the risk of atrial fibrillation (AF) in young adults and children who suffer from...
Medtronic HeartWare HVAD approved for destination therapy
The US Food and Drug Administration (FDA) has approved Medtronic’s HeartWare HVAD system as a destination therapy for patients with advanced heart failure who...
New performance and quality measures for treating heart attack patients
The American College of Cardiology (ACC) and the American Heart Association (AHA) have released updated clinical performance and quality measures to benchmark and improve...
Abbott’s Full MagLev HeartMate 3 LVAD receives FDA approval
The FDA has approved the Full MagLev HeartMate 3 (Abbott) left ventricular assist device for use in heart failure patients in need of short-term...
CE mark granted to Medtronic for Attain Stability Quad MRI SureScan active-fixation heart lead
Medtronic has received CE mark for the Attain Stability Quad MRI SureScan left heart lead. The device offers active-fixation technology, designed for precise lead...
“Singheart” offers step towards heart regeneration
New research has discovered a potential means to trigger damaged heart cells to self-heal. For the first time, researchers have identified a long non-coding...
European Heart Rhythm Association congress to become annual in 2018
The scientific congresss of the European Heart Rhythm Association (EHRA) is to become an annual event from 2018. The next congress will take place...
Heart For Heart initiative launched to improve smartphone detection of arrhythmia
Happitech, Arrhythmia Alliance and Bug Labs are to announce the launch of the Heart for Heart e-health initiative. This programme asks people to participate...
Physical activity may ward off heart damage
Physical activity can lower the risk of heart damage in middle-aged and older adults and reduce the levels of heart damage in people who...
ACC 2017: Wrist-worn heart rate monitors less accurate than standard chest strap
Researchers at Cleveland Clinic, Cleveland, USA, put five popular wrist-worn fitness trackers to the test to find out how accurately they gauge heart rate...
ACC 2017: Researchers sound alarm over Zika’s potentially harmful effects on heart
As the Zika virus continues to spread globally, new evidence has emerged about the virus’s potentially detrimental effects on the heart, according to data...
Researchers urge physicians to discuss herbal medication use with heart disease patients
Physicians should be well-versed in the herbal medications heart disease patients may take to be able to effectively discuss their clinical implications, potential benefits...
Alcohol abuse increases risk of heart conditions as much as other risk factors
Alcohol abuse increases the risk of atrial fibrillation, heart attack and congestive heart failure as much as other well-established risk factors such as high...
AHA 2016: HeartMate 3 LVAS improves clinical outcomes compared with HeartMate II LVAS
A prespecified primary analysis of the MOMENTUM 3 US IDE clinical study has indicated improvement in clinical outcomes for advanced heart failure patients implanted...
World Heart Federation launches global Roadmap to tackle atrial fibrillation
With the aim to help prevent atrial fibrillation (AF) and to improve its management worldwide— particularly in low- and middle-income countries—the World Heart Federation...
Study validates new in-hospital mortality risk model for heart attack patients
The ACTION Registry-GWTG in-hospital mortality risk model for heart attack patients has been updated to include cardiac arrest, and validated as a robust instrument...
Medtronic to acquire HeartWare for US$1.1 billion
Medtronic has entered into a definitive agreement to acquire HeartWare for approximately US$1.1 billion.
HeartWare’s flagship product, the HVAD system, features the world’s smallest full-support...
St Jude Medical HeartMate 3 wins CARDIOSTIM-EHRA EUROPACE 2016 Innovation Award
St Jude Medical has received an Innovation Award for its HeartMate 3 left ventricular assist system (LVAS) at the 2016 CARDIOSTIM EHRA EUROPACE International...
Cell Therapy grants Japan license to Daiichi Sankyo for Heartcel
Cell Therapy has granted the Japan license for its innovative cardiac regeneration medicine, Heartcel (immuno-modulatory progenitor (iMP) cells) to Daiichi Sankyo.
Adults with congenital heart defects at considerably higher risk of stroke
A study has shown heart failure, diabetes and recent heart attacks to be the strongest predictors of stroke caused by a blocked artery.
The American Heart Association and Heart Rhythm Society coordinate to improve cardiovascular research and...
The American Heart Association (AHA) and Heart Rhythm Society (HRS) have announced a collaboration designed to improve the quality of care of atrial fibrillation (AFib) patients and advance to cardiovascular research.
St Jude Medical announces CE mark approval for the HeartMate 3 Left Ventricular Assist...
St Jude Medical has announced that it has received CE mark approval for the HeartMate 3 Left Ventricular Assist System (LVAS). This is a cardiac support option for advanced heart failure patients awaiting transplantation who are not candidates for heart transplantation, or in myocardial recovery.
E-health vital in battle against heart disease say European cardiology leaders
A European Society of Cardiology (ESC) position paper published in European Heart Journal outlines how the ESC will exploit e-health in education and research, while tackling issues of quality control and data security.
Addressing social factors critical for continued fight against heart disease and stroke in the...
Deaths from heart attacks, strokes and other heart diseases have been declining, but social factors, including race, income, environment and education could reverse that trend.
Fibrin and stem cell patches show promise for heart healing
findings of a study demonstrate the promise in regenerating cardiac tissue using engineered patches made up of a mixture of fibrin and mesenchymal stem cells (MSCs) derived from human umbilical cord blood.
CVRx Barostim Therapy clinical trial results to be presented at Heart Rhythm Society 2015
Safety and efficacy results comparing patients previously treated with cardiac resynchronisation therapy to patients without cardiac resynchronisation therapy will be presented by Michael Zile from the Medical University of South Carolina, USA.
HeartWare achieves primary endpoint in the ENDURANCE destination therapy clinical trial
Investigators report data from first cohort in destination therapy at the 35th annual International Society for Heart and Lung Transplantation Meeting in Nice, France.
Cleveland Heart International and CU Medical roll out external defibrillator technology in the USA
Cleveland Heart International to acquire majority interest in Korean automatic external defibrillators manufacturer CU Medical.
New research reports low rate of mechanical failure in Optim family leads during long-term...
A new study evaluating Optim-insulated implantable cardioverter defibrillator leads found low rates of all-cause mechanical failure during a median follow-up of 3.2 years.
The challenge of catheter ablation in congenital heart disease patients
Dominic Abrams (Division of Cardiac Electrophysiology, Boston Children's Hospital, Boston, USA) writes on the importance of arrhythmia management in congenital heart disease patients and identifies the reasons why it remains a major challenge for interventional eletrophysiology.
The incidence of sudden death in heart transplant patients has not improved over the...
A first, large multicentre study in the United States has found that despite the advances in clinical management strategies after heart transplantation, there has not been an improvement in the incidence of sudden cardiac death (SCD) in heart transplant patients over the last three decades.
Updated advice on heart devices from NICE
In final draft guidance, the National Institute for Health and Care Excellence (NICE) has clearly defined which implantable cardiac devices are the most clinically and cost effective. The fresh guidance will help people with a variety of heart conditions including those with an irregular heartbeat.
St Jude Medical presents comprehensive clinical evidence during Heart Rhythm 2014
Clinical evidence about the company's cardiac rhythm management and ablation technologies will be provided in 38 sessions, including three late-breaking clinical trial sessions.
New Heart Rhythm Society Choosing Wisely list details five commonly used treatments and procedures...
The Heart Rhythm Society developed the list as part of Choosing Wisely, an initiative of the American Board of Internal Medicine Foundation launched in 2012 aimed at curbing the use of certain tests and procedures that are not supported by clinical research.
FDA issues safety communication on HeartStart automated external defibrillators
Certain HeartStart automated external defibrillator (AED) devices made by Philips Healthcare may be unable to deliver needed defibrillator shock in a cardiac emergency situation, the US Food and Drug Administration (FDA) has announced.
American College of Cardiology announces contest to recognise people living well with heart disease
Through its CardioSmart patient initiative, the American College of Cardiology is hosting a contest to find six individuals who are living well with heart disease and can inspire others to take charge of their heart health.
100th SynCardia Total Artificial Heart implanted in 2013
On 25 July, SynCardia Systems announced that 100 SynCardia temporary Total Artificial Hearts have been implanted by SynCardia certified centres in 2013.
Cell therapy and high-dose ultrasound treatment may help to improve cardiac function in hear...
A new treatment using shock wave (procedure using high-dose ultrasound) and mononuclear cells was associated with significant, albeit modest improvement in left ventricular ejection fraction (LVEF) after four months in patients with chronic postinfarction heart failure.
SynCardia certified centres to present Total Artificial Heart abstracts at International Society for Heart...
The topics include home discharge using the Freedom Portable Driver and the use of the Total Artificial Heart for adolescents, congenital patients and destination therapy.
Massachusetts General Hospital launches the Institute for Heart, Vascular and Stroke Care
According to a Massachussetts General Hospital press release this is one of the only institutes in the world to integrate cardiovascular and cerebrovascular care.
Durata and Riata ST Optim leads show low rates of insulation abrasion and mechanical...
The Population Health Research Institute analysed data from three actively monitored registries: the OPTIMUM, SCORE and SJ4 Post-Approval registries, all sponsored by St Jude Medical. The combined data from these registries currently represents 10,987 leads implanted at 293 sites.
Biotronik to showcase world’s first ICD, CRT-D and CRT-P devices with ProMRI technology at...
Biotronik will showcase the Lumax 740 ICD and CRT-D series and the Evia HF-T with ProMRI, a technology that allows patients requiring tachycardia and heart failure therapies to have access to magnetic resonance imaging.
Gene analysis helps identify basis of rare infant heart disorder
Researchers from USA have found differences in gene expression that could indicate a predisposition for histiocytoid cardiomyopathy (HC) in infants.
Sunshine Heart completes feasibility study for fully implantable C-Pulse Heart Assist System
The C-Pulse system is an investigational device designed to relieve the symptoms of heart failure, such as shortness of breath and reduced mobility, through the use of counter-pulsation technology.
FDA approves Attain Ability Plus and Attain Ability Straight left-heart leads for cardiac resynchronisation...
Attain Ability Plus enables physicians to reach and maintain the target vein, providing stability in medium-to-large venous anatomies, while Attain Ability Straight allows physicians to maneuver through small cardiac veins.
Standard pacing therapy regulates heart pumping as well as costly tailored methods
Study shows that cardiac resynchronisation therapy is as effective as two other methods that regulate the time interval between the squeezing of the heart's upper and lower chambers.
BIOTRONIK: EchoCRT clinical trial design validated with recent publication in European Heart Journal
The BIOTRONIK EchoCRT clinical trial aims to evaluate the impact of cardiac resynchronisation therapy in patients with advance heart failure.
New wireless pacemaker helps heart patients stay in touch
Doctors at Wake Forest University Baptist Medical Center's Heart Center have implanted one of the first wireless pacemakers in the US.
FDA approves new Medtronic left heart lead for CRT devices
Attain Ability lead is the first to use NASA technology in this kind of implantable medical device.
Link between diabetics who have AF and risk of heart problems and death
The ADVANCE trial has shown that type 2 diabetes patients who had AF at the start of the study had a 61% increased risk of dying from any cause.
Revolutionising access to the heart
"Epi-needle access system" developed in the University of Virginia allows physicians to go through the fluid-filled sac to the epicardium without entering the heart.
New independent data confirms benefits of CardioMEMS HF System
Northwell Health physicians presented data at the American College of Cardiology 65th Annual Scientific Session (2-4 April, Chicago, USA) showing heart failure management with the CardioMEMS HF System leads to significant improvements in quality of life and exercise capacity for patients with heart failure.
Medtronic first to receive FDA approval for MR-conditional CRT-Ds
Medtronic has announced that it is the first company to receive US Food and Drug Administration approval for magnetic resonance imaging (MRI) conditional cardiac resynchronisation therapy (CRT) defibrillators for the treatment of heart failure.
Sacubitril/valsartan now available in the UK for the treatment of HFrEF patients
Sacubitril/valsartan (Entresto, Novartis) has been made available in the UK for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction.
Patients with chronic kidney disease benefit from pacing left and right ventricles.
Cardiac resynchronisation therapy with defibrillator may prevent hospitalisation due to heart failure, when compared to treatment with implantable cardioverter defibrillator alone.
St Jude Medical completes acquisition of Thoratec
St Jude Medical has announced its completion of the previously announced acquisition of Thoratec Corporation, a global leader in mechanical circulatory support technology for the treatment of advanced heart failure.
Entresto (sacubitril valsartan) recommended by CHMP for EU approval
Pending final approval by the European Commission, Entresto (sacubitril valsartan) will be licensed for use in the UK for the treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction.
Biotronik begins first study to assess relevance of defibrillator back-up after CRT-D replacement
BioCONTINUE is the first study to investigate the relevance of defibrillator back-up following first device replacement in a heart failure patient population with a primary indication for a cardiac resynchronisation therapy defibrillator (CRT-D).
ESC announces hot line sessions highlights
Key topics from the hot line sessions of ESC 2015 include atrial fibrillation, pacing, acute myocardial infarction, heart failure, hypertension, diabetes mellitus, pharmacology and coronary artery disease.
Cecilia Linde
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset heart failure in Stockholm, the highlights of this year's EHRA EUROPACE - Cardiostim Congress and her views on what is needed to improve cardiac care in Europe.
Medtronic acquires CardioInsight Technologies
CardioInsight Technologies will now become part of the Medtronic Atrial Fibrillation Solutions business in the Cardiac Rhythm and Heart Failure division.
Michael Gold
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his views on the upcoming treatment options for heart failure and the highlights of this year's HRS meeting.
Sorin announces enrolment of first patients in the Vanguard clinical study
The Vanguard (Vagal nerve stimulation safeguarding heart failure patients) clinical study evaluates Equilia, a neurostimulation system for heart failure patients.
CVRx Barostim Therapy trial results to be presented at the ACC annual conference
CVRx completed enrolment of the 146-patient clinical trial to determine the performance of Barostim Therapy for patients suffering from chronic heart failure with advanced symptoms.
The challenge of left ventricular lead placement: What is the role of quadripolar leads?
George H Crossley (Nashville, USA) writes on the role of quadripolar leads in cardiac resynchronisation therapy to treat heart failure patients.
CardioMEMS HF significantly reduces 30-day hospital readmission rates
Retrospective data analysis from the CHAMPION clinical trial shows significant reduction in 30-day hospital readmission rates for heart failure patients age 65 and older treated with the CardioMEMS HF system (St Jude Medical).
IN-TIME trial confirms 50% reduction in mortality in HF patients
The IN-TIME trial, which was recently published in The Lancet, demonstrated that heart failure patients' mortality can be reduced by more than 50% using Biotronik Home Monitoring.
BioControl Medical crosses enrolment milestone in INOVATE-HF study
BioControl Medical has announced that it has reached 480 randomised patients - or 70% - of the planned 650 subjects with congestive heart failure in the INOVATE-HF trial of its CardioFit system.
First implants in largest-ever global trial of cardiac resynchronisation therapy
Medtronic has announced the first implants in a clinical trial that will compare patient and healthcare system outcomes in heart failure patients who have cardiac resynchronisation therapy (CRT) devices with the AdaptivCRT feature enabled versus patients receiving standard CRT.
Medtronic Viva CRT-P gets FDA approval
Medtronic has announced the US Food and Drug Administration (FDA) approval of its newest cardiac resynchronisation therapy-pacemaker, Viva CRT-P, for indicated patients with heart failure or atrioventricular block.
IN-TIME trial results on remote monitoring published in The Lancet
Biotronik has announced that the IN-TIME study results have been published in The Lancet. The randomised, controlled trial is the first worldwide to demonstrate that automatic, implant-based remote monitoring leads to significant clinical benefits for heart failure patients.
CardioMEMS system receives approval from CMS for New Technology Add-On Payment
St Jude Medical has announced that the Center for Medicare and Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) for the CardioMEMS heart failure system.
St Jude Medical completes acquisition of CardioMEMS
St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014.
MINERVA shows delays of persistent atrial fibrillation progression with advanced pacing feature
Results from the MINERVA (Minimize right ventricular pacing to prevent atrial fibrillation and heart failure) study have found that the Reactive ATP algorithm from Medtronic reduced the development of persistent atrial fibrillation by a 58% relative reduction compared to standard pacemakers (p<0.001).
Boston Scientific joins Optum Labs as Founding Medical Device Partner
Boston Scientific Corporation has joined Optum Labs as the Founding Medical Device Partner to help pioneer new research into effective treatments for heart failure and related cardiac conditions.
Israel Ministry of Health approves clinical trials for BioControl Medical’s CardioFit system
Israel Ministry of Health has approved clinical trials of the CardioFit system in patients with chronic heart failure.
Resynchronisation in narrow QRS patients questioned
The results of the EchoCRT study show that cardiac resynchronisation therapy (CRT) does not reduce the rate of death or hospitalisation and may increase mortality in heart failure patients with a QRS duration of less than 130msec
Remede implantable device system shows “promising” results in the treatment of central sleep apnoea,...
Patients with central sleep apnoea, treated with the remede system (Respicardia), experienced a 50% decrease in apnoea-hypopnea index, improved oxygenation by over 50%, decreased arousals and improved quality of life, according to results of the remede system pilot study presented by William T Abraham at the 17th Heart Failure Society of America meeting.
SERVE-HF trial completes enrolment
SERVE-HF is an international, randomised study of 1,325 participants investigating if the treatment of central sleep apnoea improves survival and outcomes of patients with stable heart failure.
IN-TIME study shows significant reduction in all-cause mortality in ICD and CRT-D patients with...
Results from the IN-TIME study have shown a significant reduction in all-cause mortality in heart failure patients with implantable cardioverter defibrillators (ICDs) or cardiac resynchonisation therapy defibrillators (CRT-Ds) fitted with remote monitoring compared to standard care therapy.
Biventricular pacing yields superior results than conventional right-ventricular pacing in BLOCK HF trial
Data from the BLOCK HF trial demonstrated that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device, significantly improves heart failure symptoms and quality of life in patients with atrioventricular block and left ventricular systolic dysfunction.
FDA gives conditional approval to Sorin to conduct RESPOND CRT clinical trial
The trial will study the safety and effectiveness of the SonR cardiac resynchronisation therapy (CRT) optimisation system in patients with advanced heart failure.
“Not all ICD shocks are harmful”
A new sub-analysis of the MADIT-CRT multicentre trial has shown that implantable cardioverter defibrillator (ICD) shocks at the time of defibrillation threshold testing in patients with mild symptoms of heart failure are not associated with an increased risk of heart failure or death or future episodes of ventricular tachycardia and ventricular fibrillation.
Update on GENETIC-AF trial for Gencaro in Atrial Fibrillation
GENETIC-AF is projected to be a 620-patient, phase 3 study comparing Gencaro (ARCA biopharma) to metoprolol CR/XL for prevention of atrial fibrillation in patients with heart failure and left ventricular dysfunction.
St Jude Medical announces FDA approval of new version of remote patient monitoring system
The newest version of Merlin.net provides clinicians with additional insight into changes in their patients' heart failure status through advanced impedance and lead monitoring capabilities.
First patient enrolled in MIRACLE EF clinical trial
The trial seeks to evaluate the effectiveness of cardiac resynchronisation therapy-pacemakers (CRT-Ps) in symptomatic heart failure patients with mild-to-moderate structural heart disease.
Apixaban now available in the UK for the prevention of stroke and systemic embolism...
The oral anticoagulant is a new prescription only treatment option for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and one or more risk factors such as: prior stroke or transient ischaemic attack; age 75 years or older; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).
Better patient outcomes gained from biventricular pacing in patients with AV block and reduced...
Data presented at the American Heart Association's 2012 Scientific Sessions show 26% relative risk reduction in the composite of death, healthcare utilisation visits requiring IV heart failure therapy, and significant increase in left ventricular end systolic volume index among the patients receiving biventricular pacing.
Boston Scientific launches new implantable defibrillation lead in Europe and Asia
The Reliance 4-Front lead is designed to streamline surgical procedure for treatment of heart failure and sudden cardiac arrest.
Viva/Brava cardiac resynchronisation therapy devices get CE mark
Medtronic's Viva/Brava cardiac resynchronisation therapy devices (CRT-D) feature a new algorithm, called AdaptivCRT, which significantly improves heart failure patients' response rate to CRT-D therapy, as compared to historical CRT trials.
Biocontrol Medical gets FDA approval to begin second phase of INOVATE-HF study of its...
CardioFit is an implantable electrical stimulation device designed to improve heart function in patients with congestive heart failure.
UK’s NICE releases final guidance on rivaroxaban for prevention of stroke and systemic embolism...
The guidance recommends rivaroxaban for people with non-valvular atrial fibrillation who have one or more risk factors such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, prior stroke or transient ischaemic attack.
CircuLite provides updated clinical data on Synergy miniature ventricular support system in multiple presentations...
Positive clinical data support Synergy's potential to improve haemodynamics, exercise capacity and quality of life in INTERMACS 4, 5, and 6 patients with chronic heart failure.
RECORD study shows efficacy and safety for Biotronik Closed Loop Stimulation (CLS) pacemaker therapy
The RECORD investigation of CLS pacemakers is the largest to date and demonstrates excellent performance in all pacing sites within the right ventricle (apical, septal, outflow tract), and even in advanced heart failure with no difference to patients without heart failure.
FDA Advisory Panel recommends expanded indication for Medtronic cardiac resynchronisation therapy with defibrillator (CRT-D)...
FDA's Circulatory Systems Devices Advisory Panel determined that the overall clinical benefits of Medtronic cardiac resynchronisation therapy with implantable cardioverter defibrillator (CRT-D) devices outweigh the risks in treating certain mildly symptomatic heart failure patients.
More work needed to reduce strokes due to atrial fibrillation in UK
A study published in BMJ Open has found that although the number of strokes has fallen in the UK, more needs to be done to reduce the risk of stroke in patients with atrial fibrillation. Additionally, it seems that while the use of anticoagulants does not increase with increasing CHADS2 (congestive heart failure, hypertension, age, diabetes, stroke) score in patients with atrial fibrillation, the use of antiplatelets does increase
Enhanced pacemaker algorithm may potentially reduce the risk of adverse clinical outcomes, PREVENT study...
The study has indicated that enhanced atrioventricular search hysteresis algorithm reduces unnecessary right ventricular pacing which correlates with less risk of heart failure hospitalisation, mortality and atrial fibrillation.
Postmenopausal women with existing cardiovascular conditions are at an increased risk for sudden cardiac...
Researchers from the University of Pennsylvania found that previous myocardial infarction, heart failure, atrial fibrillation, physical inactivity, diabetes, and reduced kidney function are all closely associated with sudden cardiac death.
CRT significantly improves LV dyssynchrony and contractile function
New data from the MADIT-CRT study shows that cardiac resynchronisation therapy with a defibrillator (CRT-D) significantly improves both left ventricular dyssynchrony and contractile function in patients with class I or II heart failure.
Right ventricular pacing among patients with an ICD
Alon Barsheshet, University of Rochester Medical Center, Rochester, USA, spoke to Cardiac Rhythm News on how right ventricular pacing is associated with an increased risk of heart failure.
FDA approves Consulta and Syncra cardiac resynchronisation therapy-pacemaker (CRT-P) systems
Medtronic's CRT-P systems are the first to offer exclusive Optivol fluid status monitoring with complete remote follow-up for proactive heart failure management.
Cardiac resynchronisation therapy twice as effective in women
Female patients had a better result from cardiac resynchronisation therapy with defibrillator than male patients with a significant 69% reduction in death or heart failure, according to results published in the Journal of American College of Cardiology.
Analysis of patients monitored by the Latitude System shows relative reduction in risk of...
The analysis also showed that heart failure patients who transmitted weight and blood pressure data via the system experienced an additional 10% reduction in the risk of death.
MADIT-CRT data show women received greater benefit from CRT-Ds than men
The sub-analysis demonstrated that both men and women experienced benefit from CRT but women experienced a 70% reduction in heart failure events compared to a 35% reduction for men.
St Jude Medical announces sponsorship of SCD-HeFT 10-year Follow-up Study
New study will revisit patients from the groundbreaking SCD-HeFT trial to collect long-term data regarding the efficacy of ICDs in heart failure patients.
“MADIT-CRT shows compelling results”
Asymptomatic or mildly symptomatic cardiac patients randomised to an implanted CRT-D have a 34% lower risk of heart failure or death than those receiving a standard ICD.
Early research shows CRT may benefit patients with ejection fractions above 35%
A retrospective analysis from the PROSPECT study suggests the potential for CRT to benefit more than 1 million heart failure patients worldwide.
AF-CHF trial results published
Results from the first trial to examine rhythm vs. rate control in heart failure patients with atrial fibrillation have been reported in the New England Journal of Medicine.
PROFID EHRA trial enrols first patient
A clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction (MI) survivors with heart failure has enrolled its first patient....
ARIES trial shows LVAD patients who did not receive aspirin had fewer bleeding complications
Abbott has announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3 left ventricular assist device (LVAD) who did...
US FDA grants IDE approval for PROACTIVE-HF 2 study of Cordella pulmonary artery sensor
Endotronix has received investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) for a subsequent multicentre study, PROACTIVE-HF 2, which...
US FDA approval for AI-powered left ejection fraction detection device
Anumana has announced US Food and Drug Administration (FDA) 510(k) clearance for ECG-AI LEF, a breakthrough artificial intelligence (AI)-powered medical device to detect low...
ESC 2023: Analyses “support use of ICDs” for indicated patients
Medtronic has announced the results from two analyses demonstrating survival benefits and a reduction in life-threatening cardiac events with the use of implantable cardioverter...
ESC 2023: Anticoagulation should not be used in patients with AHRE until AF is...
Oral anticoagulation in patients with atrial high rate episodes (AHRE) increases bleeding without reducing a composite outcome of stroke, systemic embolism or cardiovascular death.
This...
AI model may improve detection of atrial septal defect
An artificial intelligence (AI) model may be more efficient at detecting signatures of atrial septal defect (ASD) in electrocardiograms (ECG) than traditional methods.
This is...
“Not just inventing the next stent”: The future of medtech relies on patient empowerment
Ian Meredith is a well-known figure within the field of interventional cardiology, not only for a distinguished academic and clinical career but also his...
Study confirms AI detection of HFpEF using a single echocardiogram view
Applying artificial intelligence (AI) to a single apical four chamber (A4C) view echocardiogram provides accurate information to detect heart failure with preserved ejection fraction...
First patient enrolled in MOJAVE study of DSR 2.0
Sequana Medical NV has announced that the first patient has been enrolled in the MOJAVE study, a randomised controlled Phase 1/2a study in the...
US FDA approves Biotronik’s Amvia Edge portfolio
Biotronik has announced US Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronisation therapy pacemaker (CRT-P).
In a...
Depressed ICD patients “more likely to stop medications”
Patients who feel low when having a cardiac device implanted are more likely to stop taking their heart medications than those without depression, according...
ECG-AI algorithm for early identification of amyloidosis gains US FDA breakthrough designation
Anumana has received breakthrough device designation from the US Food and Drug Administration (FDA) for its electrocardiogram (ECG) artificial intelligence (AI) algorithm designed to...
CorWave closes series C funding round
CorWave has raised €61 million to fund its first industrial deployment and entry into clinical trials.
SPI fund, managed by Bpifrance on behalf of the...
HRS 2023: BIO-LIBRA study offers insights into device treatment of non-ischaemic cardiomyopathy
Preliminary results from the BIO-LIBRA study, assessing the outcomes of device-treated ventricular arrhythmias or mortality in patients with non-ischaemic cardiomyopathy (NICM) being treated with...
Impulse Dynamics announces first implantation of combined CCM and ICD device
Impulse Dynamics has today announced the completion of the first implantation for the INTEGRA-D clinical trial, designed to evaluate the safety and efficacy of...
US FDA expands indication for Farxiga
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the USA to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent...
Medtronic mapping and ablation system shows “safety and performance” in treating AF
Medtronic have announced the 12-month findings that supported the Affera Mapping and Ablation system CE Mark, demonstrating that the Sphere-9 catheter can successfully treat...
EHRA 2023: AF patients have an average of five co-existing medical conditions
A novel software tool set to improve the management of elderly atrial fibrillation (AF) patients with multiple conditions is being designed by the EU-funded...
EHRA 2023: Electric vehicle chargers found to be safe for patients with pacemakers and...
High power electric vehicle chargers are safe for patients with pacemakers and defibrillators, according to a study published in EP Europace, a journal of...
PROACTIVE-HF pivotal trial completes enrolment
Endotronix has announced its PROACTIVE-HF pivotal study has successfully completed enrolment.
The study is designed to evaluate the safety and efficacy of the Cordella pulmonary...
Health benefits of early rhythm control come with “reasonable” costs for patients with atrial...
Patients with atrial fibrillation (AF) have been said to benefit from early rhythm control therapy, which reduces cardiovascular deaths, strokes, and other adverse outcomes...
Medtronic receives CE Mark approval for Affera mapping and ablation system to treat arrhythmias
Medtronic has announced today that it has received CE Mark for the Affera mapping and ablation system, which includes the Sphere-9 catheter and the...
Low BMI associated with cardiac tamponade during catheter ablation for atrial fibrillation
A recent analysis of a large nationwide database of patients with atrial fibrillation (AF) who underwent ablation has reported an independent association between being...
Clinical trial set to use biometrics data platform to study hypertrophic cardiomyopathy
UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink's Biometrics Data Platform. The study, consisting of 70...
Barostim misses primary endpoint in BEAT-HF postmarket trial
CVRx has announced the preliminary topline results of the BeAT-HF—Baroreflex activation therapy for heart failure—postmarket randomised clinical trial.
The BeAT-HF postmarket phase of the multicentre,...
Healthy or hazardous: Study raises “red flag” on wearable smart device interference with CIEDs
A new “red flag-raising” study has provided benchmark data on the safety of smart scales, watches and rings with bioimpedance technology for patients with...
“First study” finds six-fold increase in bradyarrhythmia diagnosis using long-term ILR screening
A retrospective analysis of randomised clinical trials has found that one in five patients aged 70 years or older with cardiovascular risk factors are...
GE HealthCare to acquire AI ultrasound developer Caption Health
GE HealthCare has signed an agreement to acquire Caption Health, a developer of artificial intelligence (AI)-driven ultrasound technology.
The Caption Health technology—Caption AI—has been developed...
Accelerated pacing rate benefits HFpEF patients with pacemakers
Among patients with heart failure with preserved ejection fraction (HFpEF) and a pacemaker, treatment with a moderately accelerated, personalised pacing rate resulted in an...
CardiacSense receives FDA clearance for medical watch
CardiacSense, a digital health company that developed the world's most advanced, medically certified wearable device for monitoring vital signs, announced receipt of US Food...
Ablation as first-line treatment cuts AF progression compared to antiarrhythmic drugs
Ablation as a first-line treatment for atrial fibrillation (AF) disease is associated with significantly better clinical outcomes than starting with antiarrhythmic drugs.
These were the...
Johnson & Johnson is to acquire Abiomed
Johnson & Johnson is to acquire Abiomed, it was announced today, after the two organisations entered into a definitive agreement under which Johnson &...
Puzzle Medical wins 2022 TCT Shark Tank innovation competition
Puzzle Medical Devices was announced as the winner of the Shark Tank innovation competition at the 2022 Transcatheter Cardiovascular Therapeutics meeting (TCT, 16–19 September,...
Researchers find link between COVID-19 and new-onset AF
A study in Circulation: Arrhythmia and Electrophysiology has identified new-onset atrial fibrillation (AF) in one in 20 patients hospitalised with COVID-19.
Using data from the...
ESC 2022: Findings of CAPLA trial “do not support inclusion of posterior wall isolation”...
The addition of posterior wall isolation (PWI) does not improve arrhythmia outcomes compared with pulmonary vein isolation (PVI) alone in patients undergoing first time...
ESC 2022: Risk score predicts mortality for AF patients after TAVI
Researchers have developed a risk score to predict mortality for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation...
ESC 2022: Guidelines call for public engagement in tackling sudden cardiac death
New guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death have been published today in the European...
ESC 2022: Medical cannabis users “at elevated risk” of arrhythmia
Cannabis prescribed for chronic pain is associated with an elevated risk of heart rhythm disorders, according to research presented at the European Society of...
First-in-man study yields promising results for saline-enhanced radio frequency VT ablation
A first-in-human multicentre trial using in-catheter, heated saline-enhanced radio frequency (SERF) ablation for patients with ventricular tachycardia (VT) has reported that the technique showed...
“Worrisome” rise in cardiovascular disease predicted out to 2060
Projected rates of cardiovascular risk factors and disease will increase significantly in the USA by 2060, a study published in the Journal of the...
Genetic “cure” for cardiomyopathy is selected as winner of Big Beat Challenge
A project to develop genetic therapies to effectively cure cardiomyopathy has been announced as the winner of the British Heart Foundation’s Big Beat Challenge,...
Analysis sets out generalisability of EAST-AFNET 4 trial findings
Around 80% of patients diagnosed with atrial fibrillation (AF) in the UK population are eligible for early rhythm control, an analysis of the EAST-AFNET...
Catheter ablation “economically attractive” compared to drug therapy for AF
Catheter ablation of atrial fibrillation (AF) was economically attractive compared with drug therapy in the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial...
CardiNor agrees US distribution agreement with IBL-America
Cardiac testing company CardiNor AS has announced that it has signed an exclusive agreement with IBL-America for sales of the CardiNor Secretoneurin ELISA test...
Air pollution exposure may heighten risk of ventricular arrhythmias in ICD patients
Incidence of ventricular arrhythmias can be linked to days when air pollution is high, according to research presented at Heart Failure 2022 (21–24 May,...
HRS 2022: S-ICD can be considered as an alternative to transvenous devices in patients...
The use of a subcutaneous-implantable defibrillator (S-ICD, Boston Scientific) reduced the rate of major, lead-related complications by as much as 92% when compared to...
Cordella meets safety and efficacy endpoints in SIRONA 2 clinical trial
Endotronix has announced data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella pulmonary artery pressure sensor system in New...
HRS 2022: AI-based app used to detect left-ventricular dysfunction
Use of an artificial intelligence (AI)-based app using electrocardiogram (ECG) signals recorded with an Apple Watch is able to identify left-ventricular dysfunction, research presented...
HRS 2022: Trio of studies demonstrate positive outcomes of CSP for patients needing CRT
The Heart Rhythm Society (HRS) has announced the findings of three clinical trials demonstrating positive outcomes of conduction system pacing (CSP) for patients in...
HRS 2022: Aggressive blood pressure control reduces risk of left ventricular conduction disease
Results from a new clinical trial found aggressive blood pressure (BP) control reduced the risk of left-ventricular conduction disease. This study is the first...
EHRA 2022: ECG reading could pinpoint COVID-19 patients at high risk
A simple electrocardiogram (ECG) can pinpoint hospitalised COVID-19 patients at high risk of death who might need intensive management, according to the authors of...
EHRA 2022: Overweight patients at greater risk of AF recurrence
Overweight patients with atrial fibrillation (AF) are more likely to experience a return of the heart rhythm disorder after a corrective procedure than those...
Algorithm could enhance prevention of sudden cardiac arrest
Researchers have developed a clinical algorithm that distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.
The findings, Journal of the American...
Partnership to promote wearable tech in cardiology trials
Wearable technology and digital health specialist Activinsights has announced a partnership agreement with the cardiovascular research organisation Cardialysis to promote the use of remote...
UK study shows lack of awareness over signs of arrhythmia
Fewer than half of UK citizens are aware of the link between arrhythmia and stroke, while around one in five people with a personal...
Ceryx Medical launches Cysoni bionic device for respiratory sinus arrhythmia
A collaboration between Ceryx Medical Limited and the scientists at the Auckland Bioengineering Institute (ABI) and the Universities of Bath and Bristol, have developed...
Endotronix announces FDA approval for PROACTIVE-HF pivotal trial design change
Endotronix has announced that the US Food and Drug Administration (FDA) has granted approval for an amendment to the company's PROACTIVE-HF study, a pivotal...
Restore Medical announces preliminary results from first-in-human use of ContraBand
Restore Medical has announced preliminary results of the first-in-human clinical trial of ContraBand, a breakthrough treatment for patients suffering from congestive heart failure. The...
Cardialen gets FDA approval for study of its Multipulse Therapy for AF
Cardialen has received approval from the US Food and Drug Administration (FDA) for an investigational device exemption (IDE) to begin a clinical trial of...
What to expect from AHA 2021
Ahead of the American Heart Association’s 2021 annual scientific sessions (AHA 2021, 13–15 November, virtual), Cardiac Rhythm News speaks to the meeting’s programme committee...
Vektor Medical’s vMap receives FDA 510(k) clearance
Vektor Medical has announced US Food and Drug Administration (FDA) 510(k) clearance for its novel computational electrocardiogram (ECG) mapping system, vMap.
vMap is designed to...
Vuno’s AI-based ECG analysis software gains breakthrough designation
South Korean artificial intelligence (AI) developer Vuno has announced that the Korean Ministry of Food and Drug Safety (KFDA) has designated the company's AI-based...
Study shows safety and efficacy of robotic-guided ablation to treat paediatric arrhythmias
Stereotaxis has announced publication of a study in the International Journal of Cardiology: Heart & Vascular demonstrating superior safety and efficacy of Stereotaxis’ robotic...
APAF-CRT: Ablation and CRT beat drug therapy in permanent AF patients with narrow QRS
Ablation plus cardiac resynchronisation therapy (CRT) is superior to pharmacological rate control in reducing mortality in severely symptomatic permanent atrial fibrillation (AF) patients with...
Medtronic leads pilot programme to address disparities in sudden cardiac arrest care
Medtronic has announced a pilot programme with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest (SCA), a condition...
Zoll signs agreement to acquire Itamar Medical
Zoll Medical and Itamar Medical have announced that the two companies signed a definitive agreement under which Zoll Medical will acquire all outstanding ordinary...
Use of the antibiotic-eluting envelope in CIEDs: Has it reached prime time?
Bhargav Vemulapalli, Shreya Srivastava and John Kassotis (New Brunswick, USA) review the potential use of antibiotic-eluting envelopes (ABEs) based on available clinical data, while...
New ESC guidelines on cardiac pacing and CRT published
The European Society of Cardiology (ESC) Guidelines on cardiac pacing and cardiac resynchronisation therapy (CRT) have been published online in European Heart Journal.
The use...
ESC 2021: ACTIVE-AF finds benefits for exercise programme in AF patients
A six-month exercise programme helps maintain normal heart rhythm and reduces the severity of symptoms in patients with atrial fibrillation (AF), according to late-breaking...
Ultromics completes US$33 million Series B funding round
Ultromics, a developer of AI enabled cardiovascular imaging solutions, has announced that it has raised US$33 million in a Series B funding round. The...
Night shift work may be linked to increased risk of AF
People who work night shifts are at increased risk of developing atrial fibrillation (AF), according to research published in the European Heart Journal.
The study...
Caption Health gains NTAP authorisation from CMS for AI-guided ultrasound platform
Caption Health has announced that the Centers for Medicare and Medicaid Services (CMS) have approved new technology add-on payments (NTAP) for the Caption Guidance...
Women underrepresented in cardiovascular clinical trials
Women remain underrepresented in cardiovascular clinical trials despite initiatives to ensure broader inclusivity. This is according to two reports, both published in the last...
Tyrx envelope shown to be cost effective in European healthcare markets
Economic analyses from the WRAP-IT study, sponsored by Medtronic, demonstrate the Tyrx cardiac absorbable antibacterial envelope’s (Tyrx Envelope) cost effectiveness in European markets for...
HRS 2021: CABANA analysis points to economic case for catheter ablation
A new analysis of the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation) suggests that catheter ablation offers positive economic outcomes compared...
MicroPort enters into Series C financing agreements
MicroPort Cardiac Rhythm Management (CRM) has entered into definitive agreements in connection with its Series C financing with total investment proceeds of US$150 million.
Hillhouse...
Cardiac rehabilitation reduces rehospitalisation, death in ICD recipients
People who made even small increases in their daily physical activity levels after receiving an implantable cardioverter defibrillator (ICD) experienced fewer incidences of hospitalisation...
CABANA trial shows favourable results for catheter ablation among ethnic minority patients
Among racial or ethnic minority patients enrolled in the North American cohort of the CABANA (Catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation)...
AHA statement on AF and HFrEF positive for catheter ablation
The American Heart Association (AHA) has this week issued a scientific statement on the management of atrial fibrillation (AF) in patients with heart failure...
GE Healthcare and ACC partner to advance AI in cardiology
GE Healthcare is collaborating with the American College of Cardiology (ACC) through support of and participation in the ACC’s Applied Health Innovation Consortium for...
Abiomed acquires breakthrough device company preCARDIA
Abiomed has acquired preCARDIA, developer of a proprietary catheter and controller to expand options for patients with acute decompensated heart failure (ADHF). The preCARDIA...
EHRA 2021: Subcutaneous ICDs maintain cardioversion efficacy of 98% across five-year study
Subcutaneous implantable cardioverter defibrillator (S-ICD) devices have demonstrated a cardioversion efficacy rate of 98% over a period of at least five years in the...
EHRA 2021: Efforts should be made to increase participation in atrial fibrillation screening
Further efforts should be made to increase participation in atrial fibrillation (AF) screening—particularly in elderly populations, where systematic screening for AF can help to...
Putting the patient at the centre of the AF treatment strategy
This article was sponsored by Biosense Webster
Putting the patient at the centre of the discussion is vital to setting the right strategy for the...
COVID-19 “lays the foundation for a digital shift in cardiovascular care”
More patients, particularly those with medical risk factors or from underserved communities, opted into telehealth appointments for their cardiovascular care during the COVID-19 pandemic,...
Charity targets vaccine centres for opportunistic AF screening campaign
AF Association has launched an opportunistic screening programme to DETECT atrial fibrillation (AF) at COVID-19 vaccination clinics across the UK. The charity has created...
Mavacamten granted US FDA new drug application
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for mavacamten, an investigational,...
ACC.21 late-breaking clinical trial programme announced
The American College of Cardiology (ACC) has announced a number of the late-breaking clinical trials to be presented at its 70th annual scientific session...
“Strong evidence” of a causal link between high blood pressure and AF
A study published in the European Journal of Preventive Cardiology provides “strong evidence” of a causal relationship between elevated blood pressure and atrial fibrillation...
Richer European countries have higher AF death rates than their less wealthy neighbours
The wealthiest countries in Europe have higher death rates from atrial fibrillation (AF) than the least wealthy and these death rates are increasing more...
Remote technology in cardiac care is “here to stay”
Robert Klempfner, is director of the Israeli Center for Cardiovascular Research, and director of the Cardiovascular Prevention and the Cardiac Rehabilitation Institutes at Sheba...
Regular alcohol consumption linked to increased AF risk
A study of nearly 108,000 people has found that people who regularly drink a modest amount of alcohol are at increased risk of atrial...
Patient enrolment begins in Astral-4LV clinical trial
MicroPort Cardio Rhythm Management (CRM) has announced the first enrolment in the Astral-4LV clinical trial to evaluate the safety and efficiency of Axone, a...
Heavy alcohol consumption leads to higher stroke risk in AF patients
Fourteen drinks a week is linked with a higher risk of stroke and embolism in patients with atrial fibrillation (AF), according to research published...
AHA 2020: Rivaroxaban may be comparable to warfarin for bioprosthetic mitral valves, AF
The primary results from the RIVER Trial—Rivaroxaban for Valvular Heart disease and Atrial Fibrillation—show that rivaroxaban is comparable to warfarin for patients with bioprosthetic...
Procedural success comparable in CRT implants and upgrades
Rates of procedural success and complications were no different between de novo cardiac resynchronisation therapy (CRT) implantations and upgrades, a study published in JACC:...
High-risk surgery patients vulnerable to cardiovascular diseases
One in five high-risk patients undergoing major non-cardiac surgery will develop one or more heart complications within a year, according to research published today...
Catheter ablation linked to lower incidence of dementia in AF patients
People with atrial fibrillation (AF) have a reduced risk of dementia if they undergo catheter ablation to restore the normal rhythm of their heart,...
US FDA approves Biosense Webster’s Thermocool Smarttouch SF ablation catheter
Johnson & Johnson Medical Devices Companies has announced the US Food and Drug Administration (FDA) approval of Biosense Webster’s Thermocool Smarttouch SF ablation catheter...
Study finds over 2,000 excess cardiovascular deaths in England and Wales during pandemic
Research has identified 2,085 excess deaths in England and Wales linked to cardiovascular disease during the peak of the COVID-19 pandemic. On average, that...
Twin studies demonstrate the evolving S-ICD evidence-base
This advertorial has been sponsored by Boston Scientific
Two landmark studies have been published in 2020 following the use of subcutaneous implantable cardioverter defibrillator (S-ICDs)...
VivaLNK wearable ECG to be used in AF biomarkers study
VivaLNK has announced that the University of California, San Francisco (UCSF) (San Francisco, USA), will be utilising its continuous wearable electrocardiogram (ECG) sensor for...
Breakthrough status for Medtronic’s Tyrx for use with ventricular assist devices
Medtronic has received Breakthrough Device Designation status from the US Food and Drug Administration (FDA) for the Tyrx absorbable antibacterial driveline wrap, which is...
Medtronic’s TYRX envelope found to be cost effective for patients at increased risk of...
Medtronic has announced new data from the WRAP-IT study, showing the TYRX absorbable antibacterial envelope (TYRX Envelope) is cost effective for patients at increased...
ESC 2020 Congress: Digoxin found to be favourable in rate control for permanent AF...
Digoxin should be considered as a first-line approach for rate control in patients with permanent atrial fibrillation (AF). This was the conclusion of the...
ESC Congress 2020: EAST-AFNET 4 finds early rhythm control improves AF outcomes
Patients with newly diagnosed atrial fibrillation benefit from early rhythm control therapy, according to results of the EAST-AFNET 4 trial presented in a Hot...
Fitness linked to lower arrhythmia recurrence after AF ablation
Patients undergoing atrial fibrillation (AF) ablation, who are physically fit before the procedure, have a much higher chance of benefiting from the procedure and...
Eko and AstraZeneca announce digital cardiovascular health partnership
Eko has announced a collaboration with AstraZeneca to accelerate the development of digital health tools for the earlier screening of cardiovascular diseases, including heart...